Change gout: how to deal with this “silently-developing killer” in everyday clinical practice

References

• Punzi L. Change gout: the need for a new approach. Minerva Med 2017;108:341-9
   PubMed Web of Science ®Google Scholar
• Trifirò G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis 2013;72:694-700
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011;63:3136-41
   PubMed Web of Science ®Google Scholar
• Keenan RT. Limitations of the current standards of care for treating gout and crystal deposition in the primary care setting: a review. Clin Ther 2017;39:430-41
   PubMed Web of Science ®Google Scholar
• Pascual E, Addadi L, Andrés M, et al. Mechanisms of crystal formation in gout. Nat Rev Rheumatol 2015;11:725-30
   PubMed Web of Science ®Google Scholar
• Punzi L, So A. Serum uric acid and gout: from the past to molecular biology. Curr Med Res Opin 2013;29(Suppl 3):3-8
   PubMedGoogle Scholar
• Merriman TR, Dalbeth N, Johnson RJ. Sugar-sweetened beverages, urate, gout and genetic interaction. Pac Health Dialog 2014;20:31-8
   PubMedGoogle Scholar
• Sakellariou G, Conaghan PG, Zhang W, et al. EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Ann Rheum Dis 2017;76:1484-94
   PubMed Web of Science ®Google Scholar
• Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007;3:443-9
   PubMedGoogle Scholar
• Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11
   PubMed Web of Science ®Google Scholar
• Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 2015;67:2557-68
   PubMed Web of Science ®Google Scholar
• Ning TC, Keenan RT. Unusual clinical presentations of gout. Curr Opin Rheumatol 2010;22:181-7
   PubMed Web of Science ®Google Scholar
• Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765-70
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29-42
   PubMed Web of Science ®Google Scholar
• Medea G, Di Giacinto G. La gestione del paziente con gotta in Medicina. MeDia. 2014;14:254-9. Available at: http://www.diabete-rivistamedia.it/wp-content/uploads/2015/04/16_FOCUS_Medea1.pdf [Last accessed 14 March 2018]
   Google Scholar
• Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014;26:186-91
   PubMed Web of Science ®Google Scholar
• Scire CA, Manara M, Cimmino MA, et al. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther 2013;15:R101
   PubMed Web of Science ®Google Scholar
• Stamp L, Dalbeth N. Screening for hyperuricaemia and gout: a perspective and research agenda. Nat Rev Rheumatol 2014;10:752-6
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther 2015;32:31-41
   PubMed Web of Science ®Google Scholar
• Doghramji PP, Fermer S, Wood R, et al. Management of gout in the real world: current practice versus guideline recommendations. Postgrad Med 2016;128:106-14
   PubMed Web of Science ®Google Scholar
• Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002;29:1350-5
   PubMed Web of Science ®Google Scholar
• Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 2012;3:764
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Herrero-Beites AM. Managing gout in primary care. New York, NY: Springer Healthcare Communications; 2014
   Google Scholar
• Johnson RJ. Why focus on uric acid? Curr Med Res Opin 2015;31(Suppl 2):3-7
   PubMedGoogle Scholar
• Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 2013;9:13-23
   PubMed Web of Science ®Google Scholar
• Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015;33:1729-41
   PubMed Web of Science ®Google Scholar
• Stack A, Manolis AJ, Ritz E. Detrimental role of hyperuricemia on the cardio-reno-vascular system. Curr Med Res Opin 2015;31(Suppl 2):21-6
   PubMedGoogle Scholar
• Biscaglia S, Ceconi C, Malagù M, et al. Uric acid and coronary artery disease: an elusive link deserving further attention. Int J Cardiol 2016;213:28-32
   PubMed Web of Science ®Google Scholar
• Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:102-10
   PubMed Web of Science ®Google Scholar
• Ejaz AA, Kambhampati G, Ejaz NI, et al. Post-operative serum uric acid and acute kidney injury. J Nephrol 2012;25:497-505
   PubMed Web of Science ®Google Scholar
• Lapsia V, Johnson RJ, Dass B, et al. Elevated uric acid increases the risk for acute kidney injury. Am J Med 2012;125:302.e9-17
   Web of Science ®Google Scholar
• Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009;58:1668-71
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014;73:177-82
   PubMed Web of Science ®Google Scholar
• Viazzi F, Bonino B, Cappadona F, et al. The uric acid cardio-nephropathy. G Ital Nefrol 2017;34(Suppl 69):41-8
   PubMedGoogle Scholar
• Keenan T, Zhao W, Rasheed A, et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol 2016;67:407-16
   PubMed Web of Science ®Google Scholar
• Martínez-Quintana E, Tugores A, Rodríguez-González F. Serum uric acid levels and cardiovascular disease: the Gordian knot. J Thorac Dis 2016;8:E1462-E1466
   PubMed Web of Science ®Google Scholar
• Rai SK, Burns LC, De Vera MA, et al. The economic burden of gout: a systematic review. Semin Arthritis Rheum 2015;45:75-80
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Desideri G, Saragoni S, et al. Hyperuricemia is associated with increased hospitalization risk and healthcare costs: evidence from an administrative database in Italy. Nutr Metab Cardiovasc Dis 2016;26:951-61
   PubMed Web of Science ®Google Scholar
• Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4
   PubMed Web of Science ®Google Scholar
• Grassi W, De Angelis R. Clinical features of gout. Reumatismo 2012;63:238-45
   PubMedGoogle Scholar
• Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010;62:3237-48
   PubMed Web of Science ®Google Scholar
• Burns CM, Wortmann RL. Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis 2012;3:271-86
   PubMedGoogle Scholar
• Oderda GM, Shiozawa A, Walsh M, et al. Physician adherence to ACR gout treatment guidelines: perception versus practice. Postgrad Med 2014;126:257-67
   PubMed Web of Science ®Google Scholar
• Singh JA, Hodges JS, Toscano JP, et al. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007;57:822-9
   PubMed Web of Science ®Google Scholar
• Owens D, Whelan B, McCarthy G. A survey of the management of gout in primary care. Ir Med J 2008;101:147-9
   PubMedGoogle Scholar
• Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004;51:1023-9
   PubMed Web of Science ®Google Scholar
• Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005;52:283-9
   PubMed Web of Science ®Google Scholar
• Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum 2007;57:816-21
   PubMed Web of Science ®Google Scholar
• Choi JW, Ford ES, Gao X, et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008;59:109-16
   PubMed Web of Science ®Google Scholar
• Juraschek SP, Miller ER 3rd, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 2011;63:1295-306
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8
   PubMed Web of Science ®Google Scholar
• Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum 2015;45:174-83
   PubMed Web of Science ®Google Scholar
• Rees F, Jenins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013;72:826-30
   PubMed Web of Science ®Google Scholar
• Frampton JE. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs 2015;75:427-38
   PubMed Web of Science ®Google Scholar
• Richette P, Bardin T. Gout. Lancet 2010;375:318-28
   PubMed Web of Science ®Google Scholar
• Choi HJ, Lee YJ, Park JJ, et al. The effect of low-dose aspirin on serum and urinary uric acid levels in gouty arthritis patients. J Kor Rheum Assoc 2006;13:203-8
   Google Scholar
• Miner J, Tan PK, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther 2016;18:214
   PubMed Web of Science ®Google Scholar
• Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis 2017;76:811-20
   PubMed Web of Science ®Google Scholar
• Perez Ruiz F, Bardin T, So A. Time to control gout and make it crystal clear. EMJ Rheumatol 2017;5(Suppl 12):2-10
   Google Scholar
• Deeks ED. Lesinurad: a review in hyperuricaemia of gout. Drugs Aging 2017;34:401-10
   PubMed Web of Science ®Google Scholar
• Shen Z, Tieu K, Wilson D, et al. Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and commonly used drugs for gout treatment. Clin Pharmacol Drug Dev 2017;6:377-87
   PubMed Web of Science ®Google Scholar
• Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol 2017;69:203-12
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: a phase iii clinical trial. Arthritis Rheumatol 2017;69:1903-13
   PubMed Web of Science ®Google Scholar